The primary endpoint was overall survival (OS) for the combination versus sorafenib and secondary endpoints included OS for durvalumab versus sorafenib, objective response rate and progression-free survival (PFS) for the combination and for Durvalumab alone. The trial showed a positive and significant benefit for OS for the combination of Tremelimumab & Durvalumab vs Sorafenib.
